UK's first early-stage medtech VC (est. 2021). Fund TCX-1 closed £27m in first close (Mar 2025, target £50m), backed by British Business Bank. 3 GPs + 5-person team. Portfolio: Salient Bio, Bloom43/Plexāā (wound healing), Significare. Value-add: deep commercialization expertise, US market navigation, regulatory guidance for international expansion.
Investment Thesis
Early-stage medtech VC. Seed-Series A. Invests exc. in digital health platforms & fast-track medical devices addressing chronic conditions, women's health, oncology, mental health, care delivery. All-female GP team. Strong commercialization support & US market entry expertise. Requires direct patient experience transformation (rejects backend-only tools). Gender-smart investing lens. UK-founded cos. with global ambitions only.
Interested in connecting?
Visit their website or reach out directly.